7,107 Duloxetine Bottles Recalled Over Cancer-Causing Contaminants

Karmactive Staff

Photo Source: Pixabay

Rising Pharmaceuticals recalled 7,107 duloxetine vials because they contained N-nitroso-duloxetine.

20 mg duloxetine pills are the subject of the recall, which was started on November 19, 2024.

Photo Source: Tibor Kádek (CC BY-SA 3.0)

Photo Source: VillalobosGoPack (CC BY-SA 4.0)

One nitrosamine associated with an increased risk of cancer is N-nitroso-duloxetine.

The FDA has categorized the recall as Class II, which denotes transient or reversible health hazards.

Photo Source: Beyond My Ken (CC BY-SA 3.0)

Photo Source: Purpy Pupple (CC BY-SA 3.0)

The FDA keeps an eye on the amount of nitrosamine in medications and suggests recalls when levels rise above acceptable bounds.

Every year, more than 18 million Americans take duloxetine to treat anxiety and depression.

Photo Source: Sander van der Wel (CC BY-SA 2.0)

Photo Source: Julphar.uae (CC BY-SA 4.0)

When products are manufactured, stored, or packaged, nitrosamines may develop.

In October 2024, Towa Pharmaceutical Europe's Cymbalta was the subject of a prior recall.

Photo Source: Tokumeigakarinoaoshima (CC BY-SA 4.0)

Photo source: Alex Proimos (CC BY 2.0)

Before stopping the use of duloxetine, the FDA recommends speaking with medical professionals.